{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:17:43Z","timestamp":1768979863398,"version":"3.49.0"},"reference-count":52,"publisher":"Portland Press Ltd.","issue":"3","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":192,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Lymphoma is a group of blood cell tumors which develop from lymphocytes. The main forms of lymphoma are Hodgkin lymphoma (HL) and non-HL (NHL). Cytokines may contribute to lymphoma and they are related to risk NHL and HL. Aim: Assessment of the serum level of certain inflammatory markers as complementary indicators to confirm diagnosis of lymphoma patients that may be subjected to more invasive biopsy methods. Method: The serum levels of interleukin (IL)-1\u03b2 (IL-1\u03b2), IL-6, IL-10, tumor necrosis factor-\u03b1 (TNF-\u03b1), monocyte chemotactic protein-1 (MCP-1), granulocyte colony-stimulating factor (G-CSF), and eotaxin were assessed by Bio-Plex Pro assays in 81 lymphoma patients and 44 NHL and 37 HL patients before and after chemotherapy treatment as well as 20 healthy persons as a control group. Results: Lymphoma patients showed significantly raised marker levels before treatment and significantly reduced levels related to pre-treatment and controls of post-treatment for most of the markers. MCP-1 reported the highest diagnostic accuracy. G-CSF significantly raised pre-treatment and TNF-\u03b1. MCP-1 significantly increased in post treated HL compared with NHL. In order to distinguish HL from NHL, G-CSF reported the highest diagnostic accuracy. NHL patients reported complete remission (CR) and those who reported stable disease (SD) and progressive disease (PD) represented 25% and 38% respectively compared with 16% and 27% of HL patients, while partial remission (PR) of HL patients were 56% compared with 36% of NHL patients. Conclusion: Most of the markers were significantly increased in pre-treatment but significantly decreased post-treatment. However, it was not considerably enough to get better prognosis of the disease. Elevated serum levels of inflammatory markers correlate with disease severity and low benefit from treatment.<\/jats:p>","DOI":"10.1042\/bsr20182174","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T17:05:29Z","timestamp":1551287129000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prognostic value of some inflammatory markers in patients with lymphoma"],"prefix":"10.1042","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5684-9298","authenticated-orcid":false,"given":"Nahla","family":"Hamed Anber","sequence":"first","affiliation":[{"name":"Fellow of Biochemistry, Emergency Hospital, Mansoura University, Mansoura 35516, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed\u00a0H.","family":"EL-Sebaie","sequence":"additional","affiliation":[{"name":"Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-9772","authenticated-orcid":false,"given":"Noureldien\u00a0H.E.","family":"Darwish","sequence":"additional","affiliation":[{"name":"Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaker\u00a0A.","family":"Mousa","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Rensselaer, NY, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh\u00a0S.","family":"Shamaa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department\/Oncology Center, Mansoura University, Mansoura 35516, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"2021111619315035200_B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4103\/1110-1067.153957","article-title":"Treatment outcome in Egyptian lymphoma patients, 2-year results, single-center experience","volume":"39","author":"Allah","year":"2014","journal-title":"Egypt. J. Haematol."},{"key":"2021111619315035200_B2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-60761-451-7_5","article-title":"Epidemiological evidence: IgE, Allergies, and Hematopoietic malignancies","volume-title":"Cancer and IgE: Introducing the Concept of Allergooncology","author":"Martinez- Maza","year":"2010","edition":"1st"},{"key":"2021111619315035200_B3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1182\/blood-2006-11-051672","article-title":"Proposed classification of lymphoid neoplasms for epidemiologic research from the pathology working group of the International Lymphoma Consortium (InterLymph)","volume":"110","author":"Morton","year":"2007","journal-title":"Blood"},{"key":"2021111619315035200_B4","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1182\/blood-2008-01-133587","article-title":"Etiologic heterogeneity among non-Hodgkin lymphoma subtypes","volume":"112","author":"Morton","year":"2008","journal-title":"Blood"},{"key":"2021111619315035200_B5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0002-9440(10)62038-X","article-title":"Macrophage responses to hypoxia. Implications for tumor progression and anti-cancer therapies","volume":"167","author":"Lewis","year":"2005","journal-title":"Am. J. Pathol."},{"key":"2021111619315035200_B6","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1073\/pnas.1320198111","article-title":"Circulating giant macrophages as a potential biomarker of solid tumors","volume":"111","author":"Adams","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111619315035200_B7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5858\/2001-125-0067-ROLAEC","article-title":"Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing","volume":"125","author":"Lingen M","year":"2001","journal-title":"Arch. Pathol. Lab. Med"},{"key":"2021111619315035200_B8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"key":"2021111619315035200_B9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fphys.2014.00114","article-title":"The role IL-1 in tumor-mediated angiogenesis","volume":"5","author":"Voronov","year":"2014","journal-title":"Front. Physiol."},{"key":"2021111619315035200_B10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.4049\/jimmunol.164.2.762","article-title":"Autocrine production of IL-10 mediates defective IL-12 production and NF-\u03baB activation in tumor-associated macrophages","volume":"164","author":"Sica","year":"2000","journal-title":"J. Immunol."},{"key":"2021111619315035200_B11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/cytogfr.2010.09.002","article-title":"Biology of interleukin -10","volume":"21","author":"Sabat","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"2021111619315035200_B12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1365-2567.2002.01363.x","article-title":"Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumor and vascular cell proliferation","volume":"105","author":"Garc\u00eda-Hern\u00e1ndez","year":"2002","journal-title":"Immunology"},{"key":"2021111619315035200_B13","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"2021111619315035200_B14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.hoc.2007.06.014","article-title":"New strategies for the treatment of early stages of Hodgkin\u2019s lymphoma","volume":"21","author":"Marcus","year":"2007","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"2021111619315035200_B15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/1471-2407-12-288","article-title":"Is there a role for consolidative radiotherapy in the treatment of aggressive and localized Non-Hodgkin lymphoma? A systematic review with meta-analysis.","volume":"12","author":"dos Santos","year":"2012","journal-title":"BMC Cancer"},{"key":"2021111619315035200_B16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"2021111619315035200_B17","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"2021111619315035200_B18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximabvedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"2021111619315035200_B19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1586\/17474086.2015.1091301","article-title":"Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide","volume":"8","author":"Salihoglu","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"2021111619315035200_B20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/jjco\/hyp062","article-title":"Anti-angiogenic therapy against gastrointestinal tract cancers","volume":"39","author":"Iwasaki","year":"2009","journal-title":"Japanese J. Clin. Oncol."},{"key":"2021111619315035200_B21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/ph3030572","article-title":"Platelet-derived growth factor (PDGF)\/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy","volume":"3","author":"Marius","year":"2010","journal-title":"Pharmaceuticals"},{"key":"2021111619315035200_B22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3923\/ijcr.2014.96.105","article-title":"Prognostic utility of angiogenic growth factors; basic FGF, VEGF and PDGF-bb in patients with lymphoma","volume":"10","author":"Elbaz","year":"2014","journal-title":"Int. J. Cancer Res."},{"key":"2021111619315035200_B23","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1016\/j.semcancer.2015.01.001","article-title":"Broad targeting of angiogenesis for cancer prevention and therapy","volume":"35","author":"Wanga","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"2021111619315035200_B24","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1007\/s11999-010-1401-x","article-title":"A comparison of fine-needle aspiration, core biopsy, and surgical biopsy in the diagnosis of extremity soft tissue masses","volume":"468","author":"Kasraeian","year":"2010","journal-title":"Clin. Orthop. Relat. Res."},{"key":"2021111619315035200_B25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0140-6736(03)12777-8","article-title":"Hodgkin\u2019s lymphoma","volume":"361","author":"Yung","year":"2003","journal-title":"Lancet"},{"key":"2021111619315035200_B26","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"2021111619315035200_B27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"2021111619315035200_B28","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdl443","article-title":"Epidemiology of hematological malignancies","volume":"18","author":"Rodriguez-Abreu","year":"2007","journal-title":"Ann. Oncol."},{"key":"2021111619315035200_B29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3324\/haematol.2016.150656","article-title":"The emerging role of immune checkpoint inhibition in malignant lymphoma","volume":"102","author":"Hude","year":"2017","journal-title":"Haematology"},{"key":"2021111619315035200_B30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jaci.2017.03.023","article-title":"Moving towards endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis","volume":"140","author":"Thijs","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"2021111619315035200_B31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"key":"2021111619315035200_B32","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0006-291X(02)02335-5","article-title":"G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells","volume":"297","author":"Natori","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111619315035200_B33","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood-2006-04-013755","article-title":"G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism","volume":"108","author":"Capoccia","year":"2006","journal-title":"Blood"},{"key":"2021111619315035200_B34","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"2021111619315035200_B35","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/1078-0432.CCR-05-1603","article-title":"The role of interleukin1 in growth and metastasis of human cancer xenografts","author":"Elaraj","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2021111619315035200_B36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1476-5829.2010.00235.x","article-title":"Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma","volume":"9","author":"Perry","year":"2010","journal-title":"Vet. Comp. Oncol."},{"key":"2021111619315035200_B37","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s10552-010-9560-3","article-title":"Circulating cytokines and risk of B-cell non-Hodgkin lymphoma. A prospective study","volume":"21","author":"Gu","year":"2010","journal-title":"Cancer Causes Control"},{"key":"2021111619315035200_B38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5858\/2010-0060-OA.1","article-title":"Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma","volume":"135","author":"Gaiolla","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"2021111619315035200_B39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00005-010-0066-1","article-title":"Plasma TNF- \u03b1 and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-cell lymphoma in different risk groups defined by the international prognostic index","volume":"58","author":"Lech-Maranda","year":"2010","journal-title":"Arch. Immunol. Ther. Ex."},{"key":"2021111619315035200_B40","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/0008-5472.CAN-11-0165","article-title":"Pre-diagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin lymphoma","volume":"71","author":"Purdue","year":"2011","journal-title":"Cancer Res."},{"key":"2021111619315035200_B41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"2021111619315035200_B42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(05)70434-4","article-title":"Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the Inter Lymph Consortium","volume":"7","author":"Rothman","year":"2006","journal-title":"Lancet Oncol."},{"key":"2021111619315035200_B43","first-page":"4653","article-title":"Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence","volume":"9","author":"Trikha","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"2021111619315035200_B44","first-page":"3187","article-title":"Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer","volume":"26","author":"Bartsch","year":"2006","journal-title":"Anticancer Res."},{"key":"2021111619315035200_B45","doi-asserted-by":"publisher","first-page":"e8026","DOI":"10.1371\/journal.pone.0008026","article-title":"Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody","volume":"4","author":"Gougelet","year":"2009","journal-title":"PLoS ONE"},{"key":"2021111619315035200_B46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/annonc\/13.S1.52","article-title":"Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues","volume":"13","author":"Maggio","year":"2002","journal-title":"Ann. Oncol."},{"key":"2021111619315035200_B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep38671","article-title":"Cerebrospinal fluid IL-10 and IL-10\/IL-6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma","volume":"6","author":"Song","year":"2016","journal-title":"Sci. Rep."},{"key":"2021111619315035200_B48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10549-011-1855-x","article-title":"Role of interleukin-10 in breast cancer","volume":"133","author":"Hamidullah","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"2021111619315035200_B49","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1189\/jlb.0705358","article-title":"Interleukin-10 and the immune response against cancer: a counterpoint","volume":"78","author":"Mocellin","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"2021111619315035200_B50","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cncr.22999","article-title":"Interleukin-6 and its receptor in cancer: implications for translational therapeutics","volume":"110","author":"Hong","year":"2007","journal-title":"Cancer"},{"key":"2021111619315035200_B51","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin 10-receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"2021111619315035200_B52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1751-553X.2007.00951.x","article-title":"Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma","volume":"30","author":"Nacinovi\u0107-Duleti\u0107","year":"2008","journal-title":"Int. J. Lab. Hematol."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20182174\/841851\/bsr-2018-2174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20182174\/841851\/bsr-2018-2174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:22:40Z","timestamp":1637094160000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/3\/BSR20182174\/111022\/Prognostic-value-of-some-inflammatory-markers-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,29]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20182174","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3]]},"article-number":"BSR20182174"}}